![]() |
市場調查報告書
商品編碼
1965469
非PVC輸液袋市場-全球產業規模、佔有率、趨勢、機會、預測:按產品類型、材料、含量、地區和競爭格局分類,2021-2031年Non-PVC IV Bags Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Material, By Content, By Region & Competition, 2021-2031F |
||||||
全球非PVC輸液袋市場預計將從2025年的31億美元成長到2031年的45.6億美元,複合年成長率為6.64%。
這些無菌輸液容器採用聚丙烯和聚乙烯等熱可塑性橡膠製造,並經過特殊設計,不含聚氯乙烯(PVC) 和鄰苯二甲酸二(2-乙基己基)酯 (DEHP)。市場成長主要受以下因素驅動:為消除醫療廢棄物焚燒過程中有害戴奧辛排放製定的嚴格監管要求;以及臨床上迫切需要能夠防止在輸注高敏感性抗癌藥物和親油性藥物過程中化學物質滲漏的容器。根據 Practice Greenhealth 統計,截至 2024 年,在已報告的醫療機構中,包括輸液袋在內的腸外輸液產品線中不含 DEHP 和 PVC 的比例中位數已達到 38%。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 31億美元 |
| 市場規模:2031年 | 45.6億美元 |
| 複合年成長率:2026-2031年 | 6.64% |
| 成長最快的細分市場 | 多重腔 |
| 最大的市場 | 北美洲 |
然而,目前阻礙全球非PVC輸液袋市場擴張的主要障礙是其與傳統材料相比較高的製造成本。先進聚烯的複雜製造流程以及不斷上漲的原物料價格導致其價格溢價,阻礙了注重預算的醫療機構採用。因此,儘管人們意識到傳統PVC輸液袋存在環境方面的弊端,但採購決策往往優先考慮即時的經濟效益。
對化學物質滲漏的更嚴格監管以及對患者安全日益成長的擔憂,正在從根本上改變全球非聚氯乙烯會釋放致癌性的戴奧辛,所帶來的環境風險進一步加速了這個趨勢。這種材料替代的規模龐大。根據「無害醫療」(Health Care Without Harm)組織預測,到2024年7月,PVC醫療設備將佔全球醫療設備的26%,這為用更安全的替代品取代它們提供了巨大的機會。隨著監管機構實施更嚴格的標準,製造商正在重新設計其產品線,以確保更好的藥物相容性,並將對脆弱患者的毒性風險降至最低。
同時,人們對永續醫療包裝的日益關注正推動著可回收性更強的非PVC材料的普及。與PVC不同,聚丙烯等熱可塑性橡膠能夠實現更清潔的處置,並支持循環經濟的實施。百特國際於2023年12月開展的試驗計畫充分體現了該產業對環境管理的承諾,該計畫成功地將超過6噸的輸液袋廢棄物從掩埋轉移出去。為了滿足市場對這些環保產品日益成長的需求,主要市場參與者正在大幅擴大其產能。例如,2024年11月,ICU Medical宣布與大塚製藥株式會社成立合資企業,利用其年產能約14億件的綜合生產網路,加強現代靜脈輸液治療的全球供應鏈。
非聚氯乙烯(PVC)輸液袋由於製造成本高於傳統材料,在市場擴張方面面臨重大障礙。這些無菌容器的生產需要先進的聚烯和專門的加工技術,因此其成本必然高於大規模生產的傳統聚氯乙烯(PVC)產品。這種價格差異迫使醫療機構在環境目標和財務永續性之間做出艱難抉擇,往往導致他們為了保障營運資金而繼續使用成本較低的傳統輸液方案。
醫療保健產業的緊縮環境進一步加劇了這些經濟壓力。隨著營運成本的上升,採購預算捉襟見肘。美國醫院協會 (AHA) 報告稱,到 2024 年,醫院總支出將增加 5.1%,遠超過整體通貨膨脹率。面對日益沉重的財務負擔,醫療機構管理者被迫仔細審查每項耗材,以維持獲利能力。因此,非 PVC 材質的造口袋溢價更容易受到成本削減措施的影響,儘管臨床上具有許多益處,但越來越多的醫療機構仍在推遲採用。這直接阻礙了非 PVC 造口袋市場的整體成長。
即用型(RTA)靜脈輸液的出現,從根本上改變了市場動態,顯著降低了醫院藥房運作中的低效環節。與傳統的配製方式不同,RTA製劑提供無菌預混處方,避免了污染風險和給藥錯誤等問題,大幅縮短了醫護人員的配藥時間和人事費用。這種對便利性和安全性的追求,促使製造商拓展其非PVC預填充容器的產品線,以最佳化臨床處理效率,同時符合滅菌標準。例如,2024年7月,Amneel Pharmaceuticals宣布其新型無防腐劑即用型磷酸鉀注射液獲得美國FDA核准。該產品旨在簡化給藥流程,最大限度地減少臨床醫生通常需要的配製步驟。
同時,生產線的節能已成為優先事項。製造商正致力於減少生產過程本身(而非包裝袋材料)的碳足跡。業界領導企業正透過採用可再生能源技術維修設備並最佳化熱處理流程,減少範圍 1 和範圍 2 的排放,使其營運與全球淨零排放目標保持一致。這一趨勢的重點在於降低熱可塑性橡膠所需的能耗,並透過卓越的製造技術來實現環境目標。貝朗在 2024 年企業報告中強調,自 2020 年以來,透過有針對性的營運改善和資源節約措施,集團已成功將二氧化碳當量排放排放減少了 9.6%。
The Global Non-PVC IV Bags Market is projected to expand from a valuation of USD 3.10 Billion in 2025 to USD 4.56 Billion by 2031, reflecting a CAGR of 6.64%. These sterile fluid containers are crafted from thermoplastic elastomers like polypropylene or polyethylene, specifically designed to exclude polyvinyl chloride and di-2-ethylhexyl phthalate (DEHP). This market growth is largely driven by strict regulatory mandates seeking to eliminate toxic dioxin emissions during medical waste incineration, alongside the urgent clinical need for containers that prevent chemical leaching when administering sensitive oncological or lipophilic drugs. According to Practice Greenhealth, in 2024, the median share of DEHP- and PVC-free product lines within the parenteral infusion category, which includes IV bags, stood at 38% among reporting healthcare facilities.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 3.10 Billion |
| Market Size 2031 | USD 4.56 Billion |
| CAGR 2026-2031 | 6.64% |
| Fastest Growing Segment | Multi Chamber |
| Largest Market | North America |
However, a major obstacle currently slowing the wider expansion of the Global Non-PVC IV Bags Market is the higher production cost compared to legacy materials. The sophisticated manufacturing processes and increased raw material prices associated with advanced polyolefins result in a price premium that deters adoption in budget-conscious healthcare systems. Consequently, procurement decisions frequently prioritize the immediate economic efficiency of traditional PVC options, despite the known environmental disadvantages associated with them.
Market Driver
Tightening regulatory restrictions and rising patient safety concerns regarding chemical leaching are fundamentally reshaping the Global Non-PVC IV Bags Market. Healthcare systems are actively phasing out polyvinyl chloride containers to reduce risks associated with di-2-ethylhexyl phthalate (DEHP), a plasticizer linked to endocrine disruption, a shift further accelerated by the environmental hazards of incinerating chlorinated plastics which release carcinogenic dioxins. The scale of this material substitution is substantial; Health Care Without Harm noted that in July 2024, PVC medical devices comprised 26% of devices globally, presenting a massive opportunity for replacement with safer alternatives. As regulators enforce stricter standards, manufacturers are reformulating product lines to ensure superior drug compatibility and minimize toxicity risks for vulnerable patients.
Simultaneously, the increasing focus on sustainable medical packaging is boosting the adoption of non-PVC materials that offer improved recyclability. Unlike PVC, thermoplastic elastomers such as polypropylene facilitate cleaner disposal and support circular economy applications. This industry commitment to environmental stewardship was highlighted by Baxter International Inc., which concluded a pilot program in December 2023 that successfully diverted over 6 tons of IV bag waste from landfills. To meet the escalating demand for these eco-friendly products, key market players are significantly expanding their manufacturing capacities; for instance, ICU Medical, Inc. announced a joint venture with Otsuka Pharmaceutical Factory in November 2024 to leverage a combined production network of roughly 1.4 billion annual units, strengthening the global supply chain for modern infusion therapies.
Market Challenge
The higher production expense of non-PVC IV bags relative to legacy materials constitutes a significant barrier to market expansion. Manufacturing these sterile containers requires advanced polyolefins and specialized fabrication technologies that are inherently more expensive than the mass production of traditional polyvinyl chloride. This price disparity forces healthcare providers to face a difficult trade-off between environmental objectives and financial viability, often resulting in the retention of cheaper, conventional IV solutions to maintain operational liquidity.
This economic pressure is exacerbated by the tightening financial landscape of the medical sector, where rising operational costs are squeezing procurement budgets. The American Hospital Association reported that in 2024, total hospital expenses grew by 5.1%, significantly outpacing the general inflation rate. Confronted with such escalating financial burdens, healthcare administrators are compelled to scrutinize every supply line item to preserve margins. Consequently, the premium attached to non-PVC bags renders them a target for cost-containment measures, causing facilities to defer adoption despite the clinical advantages, thereby directly hampering the broader growth of the non-PVC market.
Market Trends
The emergence of Ready-to-Administer (RTA) IV Solutions is fundamentally altering market dynamics by resolving critical inefficiencies in hospital pharmacy workflows. In contrast to traditional compounding, which carries risks of contamination and dosing errors, RTA formats offer sterile, pre-mixed formulations that significantly reduce preparation time and labor costs for healthcare providers. This shift toward convenience and safety is driving manufacturers to expand their portfolios of pre-filled non-PVC containers, ensuring compliance with sterility standards while optimizing clinical throughput. For example, Amneal Pharmaceuticals announced in July 2024 that it received U.S. FDA approval for a new preservative-free, ready-to-use Potassium Phosphates Injection IV bag, designed to streamline administration and minimize the compounding steps typically required by clinicians.
Parallel to this, the implementation of energy-efficient production lines has emerged as a priority, as manufacturers strive to lower the carbon footprint of the fabrication process itself, distinct from the bag materials. Industry leaders are retrofitting facilities with renewable energy technologies and optimizing thermal processes to decrease Scope 1 and 2 emissions, aligning operational performance with global net-zero targets. This trend focuses on reducing the energy intensity required to mold thermoplastic elastomers, addressing environmental goals through manufacturing excellence. B. Braun highlighted this in its 2024 corporate report, stating that its global group successfully reduced CO2 equivalent emissions by 9.6% since 2020 through targeted operational improvements and resource conservation measures.
Report Scope
In this report, the Global Non-PVC IV Bags Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Non-PVC IV Bags Market.
Global Non-PVC IV Bags Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: